Literature DB >> 24824470

[Management of symptomatic bone metastases in urologic malignancies].

N Rolfes1, G Lümmen.   

Abstract

Bone metastases and related skeletal events are frequent complications of genitourinary malignancies. Hypercalcemia, chronic pain, pathologic bone fractures, transverse spinal cord syndromes, and myelosuppression are possible clinical signs. Treatment is usually multimodal and multidisciplinary, and covers oncologic and medical therapy, pain therapy as well as radiation therapy. In case of pathologic bone fractures or instabilities surgery might be indicated.

Entities:  

Mesh:

Year:  2014        PMID: 24824470     DOI: 10.1007/s00120-014-3516-2

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  19 in total

Review 1.  Epidural spinal cord compression: a single institution's retrospective experience.

Authors:  M C Chamberlain; P A Kormanik
Journal:  Neuro Oncol       Date:  1999-04       Impact factor: 12.300

2.  [Diagnosis and therapy of bone metastases].

Authors:  B Wippermann; E Mössinger; H E Schratt; C Krettek
Journal:  Unfallchirurg       Date:  2002-02       Impact factor: 1.000

3.  Bone marrow carcinosis and disseminated tumour cells.

Authors:  Muireann T Kelleher; Anne Kendall; Simon Chowdhury
Journal:  Onkologie       Date:  2010-01-22

Review 4.  Clinical features of metastatic bone disease and risk of skeletal morbidity.

Authors:  Robert E Coleman
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

Review 5.  Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.

Authors:  Paul J Kostenuik
Journal:  Curr Opin Pharmacol       Date:  2005-09-26       Impact factor: 5.547

Review 6.  Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease.

Authors:  Colin R Dunstan; Dieter Felsenberg; Markus J Seibel
Journal:  Nat Clin Pract Oncol       Date:  2007-01

Review 7.  Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.

Authors:  Robert W Ross; Eric J Small
Journal:  J Urol       Date:  2002-05       Impact factor: 7.450

8.  Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur.

Authors:  D B Mach; S D Rogers; M C Sabino; N M Luger; M J Schwei; J D Pomonis; C P Keyser; D R Clohisy; D J Adams; P O'Leary; P W Mantyh
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

Review 9.  [The value of biphosphonates in the therapy of prostate cancer].

Authors:  N Rolfes; G Lümmen
Journal:  Urologe A       Date:  2009-09       Impact factor: 0.639

Review 10.  Skeletal complications of malignancy.

Authors:  R E Coleman
Journal:  Cancer       Date:  1997-10-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.